Total product revenues increased by 36% over the period, with further growth from licensing and royalty income. In October, monthly sales exceeded £7m for the first time.

European product revenues continued to display strong growth at 22%, with the group's new US business contributing the balance.

Currency exchange rates accounted for 8% of growth during the period.

Sales of the group's pan-EU products - Tostran, Rectogesic and Xomolix - increased by 32%, while its top-selling product, Adcal-D3, which is marketed in the UK only, consolidated its market-leading position with sales growth of 16%.

CEO Dr Wilson Totten said the group's development pipeline now included two further products under active review in the US, with a further product expected to be refiled there in mid-2010.

Story provided by Business Financial Newswire